Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 4, 2026, 06:23Sylvie Retailleau: What Has Happened to Women in Science Since Marie Curie?
-
Apr 4, 2026, 05:58Branimir Beljin: Before You Take Ashwagandha There’s One Question That Matters
-
Apr 4, 2026, 05:52Basheer Saeed: How the Immune System Influences Pregnancy Success and Risk
-
Apr 4, 2026, 05:50Sujatha Sagiraju: Proud to Be Part of a Team at Truveta Advancing Endometriosis Research
-
Apr 4, 2026, 05:45Somer Baburek: Endometriosis Enters a New Phase as Science and Awareness Converge
-
Apr 3, 2026, 12:57Sergei Gorlovetsky: The Invisible Work Breaking Fertility Clinics
-
Apr 3, 2026, 12:50Ting Yuan: Rethinking Oocyte Quality Through Reproducible Patterns
-
Apr 3, 2026, 12:36Asma Khalil: An Incredibly Powerful Podcast Brings Attention to Women’s Fertility Challenges
-
Apr 3, 2026, 12:29Angela Koech: Every 30 Seconds, Africa Loses a Baby to a Preventable Stillbirth